



Published in final edited form as:

*J Immunol.* 2013 January 1; 190(1): 357–365. doi:10.4049/jimmunol.1201825.

## PI3K $\gamma$ signaling promotes *Campylobacter jejuni* induced colitis through neutrophil recruitment in mice

Xiaolun Sun<sup>\*</sup>, Bo Liu<sup>\*¶</sup>, Ryan Balfour Sartor<sup>\*#</sup>, and Christian Jobin<sup>\*#§</sup>

<sup>\*</sup>Department of Medicine, University of North Carolina, Chapel Hill, NC

<sup>#</sup>Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC

<sup>§</sup>Department of Pharmacology, University of North Carolina, Chapel Hill, NC

<sup>¶</sup>Institute of Zoonosis, College of Animal Science and Veterinary Medicine, Jilin University, Changchun, China

### Abstract

Crypt abscesses caused by excessive neutrophil accumulation are prominent features of human campylobacteriosis and its associated pathology. The molecular and cellular events responsible for this pathological situation are currently unknown. We investigated the contribution of PI3K $\gamma$  signaling in *Campylobacter jejuni*-induced neutrophil accumulation and intestinal inflammation. Germ-free and specific pathogen free *III10*<sup>-/-</sup> and germ-free *III10*<sup>-/-</sup>; *Rag2*<sup>-/-</sup> mice were infected with *C. jejuni* (10<sup>9</sup> CFU/mouse). PI3K $\gamma$  signaling was manipulated using either the pharmacological PI3K $\gamma$  inhibitor AS252424 (i.p. 10 mg/kg daily) or genetically using *Pi3k $\gamma$* <sup>-/-</sup> mice. After up to 14 days, inflammation was assessed histologically and by measuring levels of colonic *III1 $\beta$* , *Cxcl2* and *III17a* mRNA. Neutrophils were depleted using anti-Gr1 antibody (i.p. 0.5 mg/mouse/every 3 days). Using germ-free *III10*<sup>-/-</sup>; *Rag2*<sup>-/-</sup> mice, we observed that innate immune cells are the main cellular compartment responsible for campylobacteriosis. Pharmacological blockade of PI3K $\gamma$  signaling diminished *C. jejuni*-induced intestinal inflammation, neutrophil accumulation and NF- $\kappa$ B activity, which correlated with reduced *III1 $\beta$*  (77%), *Cxcl2* (73%) and *III17a* (72%) mRNA accumulation. Moreover, *Pi3k $\gamma$* <sup>-/-</sup> mice pretreated with anti-IL-10R were resistant to *C. jejuni*-induced intestinal inflammation compared to *Wt* mice. This improvement was accompanied by a reduction of *C. jejuni* translocation into the colon and extra-intestinal tissues and by attenuation of neutrophil migratory capacity. Furthermore, neutrophil depletion attenuated *C. jejuni*-induced crypt abscesses and intestinal inflammation. Our findings indicate that *C. jejuni*-induced PI3K $\gamma$  signaling mediates neutrophil recruitment and intestinal inflammation in *III10*<sup>-/-</sup> mice. Selective pharmacological inhibition of PI3K $\gamma$  may represent a novel means to alleviate severe cases of campylobacteriosis, especially in antibiotic-resistant strains.

### Keywords

Innate immunity; NF- $\kappa$ B; inflammation; enteric infection; crypt abscesses

Correspondence: Christian Jobin, Ph.D., University of North Carolina, Chapel Hill, NC 27599 USA, Phone: +1-919-966-7884, Fax: +1-919-966-7468, job@med.unc.edu.

**Disclosures:** The authors have declared that no competing interests exist.

#### Author Contribution:

Conceived and designed the experiments: CJ, XS. Performed the experiments: XS. Analyzed the data: XS, CJ. Contributed reagents: RBS, BL. Wrote the paper: XS, CJ.

## INTRODUCTION

*Campylobacter jejuni* is the leading cause of food borne bacterial infection worldwide and has a prevalence of 14 laboratory-confirmed cases/100,000 persons in 2011 in the United States (1). This infection rate is the second highest incidence and higher than the following eight most common pathogens combined (9.1/100,000) (1). Symptoms of *Campylobacter* infection are generally self-limited and include diarrhea, abdominal cramps and fever (2). However, severe cases involving bloody diarrhea, prolonged fever and severe cramping require antibiotic treatment. Importantly, campylobacteriosis is associated with development of extra-intestinal sequelae such as Guillain-Barre Syndrome (3), reactive arthritis(4), relapse of inflammatory bowel diseases (IBD)(5) and post-infectious irritable bowel syndrome (6). These numerous sequelae in conjunction with increased resistance to antibiotic treatment position campylobacter an important enteric pathogen and demand an improvement in both prevention and management (7, 8). Although campylobacteriosis represents a major health concern in both the developing and industrialized world, our understanding of the basic molecular and cellular events associated with *Campylobacter* infection is rather primitive compared to other pathogens with less prevalence (*Shigella*, *Escherichia*, *Vibrio*, *Listeria*) (9). This gap of knowledge is in stark contrast with the relatively well characterized molecular genetic information of the bacterium. Indeed, the publication of various campylobacter genomes, included *C. jejuni* 81–176 has contributed to a better understanding of the microbial genetic elements controlling growth, survival and fitness (10, 11). Our limited understanding of *Campylobacter* pathogenesis likely stems from the poor availability of murine models. We and others have recently showed that *III0*<sup>-/-</sup> mice represent a powerful model to study colonization, infection, bacterial translocation and inflammatory responses (12–14). Moreover, a recent study showed that the colon of *C. jejuni* infected *III0*<sup>-/-</sup> mice showed increased expression of the chemoattractant *Cxcl2* which correlates with the formation of numerous crypt abscesses and neutrophil infiltration, a phenotype commonly observed in human campylobacteriosis (13, 15). Similarly, CXCL-2 mediates neutrophil recruitment into intestinal Peyer's patches (PP) and MLN in *Salmonella*-infected mice (16), therefore this chemokine may play an important role in campylobacteriosis.

Phosphatidylinositol 3-kinases (PI3Ks) are a large family of signaling proteins formed by a catalytic subunit and a regulatory subunit. These signaling proteins are grouped into three different classes (I, II and III) and are implicated in the regulation of cell growth, proliferation, differentiation, survival and motility (17). In addition, a number of recent reports implicate various PI3K proteins in innate and adaptive immunity (17, 18). PI3K $\gamma$  is a class I B PI3K and comprises a catalytic subunit (p110 $\gamma$ ) and a regulatory subunit (p101 or p84). PI3K $\gamma$  is mainly expressed in immune cells and mediates chemoattractant-induced cell migration by controlling actin cytoskeletal rearrangement through G-protein coupled receptors (19, 20). Interestingly, neutrophils isolated from *Pi3k* $\gamma$ <sup>-/-</sup> mice show impaired migration towards N-formyl-methionyl-leucyl-phenylalanine (fMLP) due to reduced F-actin accumulation at the cell's leading edge (21). In addition, *Pi3k* $\gamma$ <sup>-/-</sup> mice injected i.p. with *Listeria* exhibited reduced neutrophil accumulation into the peritonea compared to *Wt* mice (20).

We recently found that *C. jejuni* induced intestinal inflammation is associated with neutrophil infiltration (13), although the functional impact and molecular events leading to this response remained elusive. In present study, we hypothesized that neutrophil recruitment into intestinal crypts and the associated tissue destruction observed in *C. jejuni* infected hosts are mediated through PI3K $\gamma$  signaling and neutrophil recruitment. Using pharmacological and genetic approaches, we demonstrated that PI3K $\gamma$  signaling promotes

*C. jejuni*-induced colitis by regulating the influx of neutrophils into intestinal crypts. This signaling pathway may represent a new therapeutic target for campylobacteriosis.

## MATERIALS AND METHODS

### Mice and tissue processing

All animal protocols were approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill. Germ-free 8–12 week-old *II10*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> (129/SvEv; C57BL/6 mixed background), *II10*<sup>-/-</sup> and *II10*<sup>-/-</sup>; *Rag2*<sup>-/-</sup> mice (129/SvEv) were transferred from germ-free isolators and immediately gavaged with a single dose of 10<sup>9</sup> *C. jejuni* cfu/mouse (strain 81–176(22)) and sacrificed after up to 14 days as described previously (13). Specific pathogen free (SPF) housed *Wt*, *II10*<sup>-/-</sup> and *Pi3k $\gamma$* <sup>-/-</sup> (20) mice (generous gift of Dr. Emilio Hirsch, University of Torino, Italy) all on a 129/SvEv background were gavaged 10<sup>9</sup> *C. jejuni* cfu/mouse one day after 7 day treatment with antibiotics cocktail (streptomycin 2 g/L, gentamycin 0.5 g/L, bacteriocin 1 g/L and ciprofloxacin 0.125 g/L) (13). To inhibit PI3K and PI3K $\gamma$  signaling, mice were i.p. injected daily with wortmannin (1.4 mg/kg; Fisher Scientific) and AS252424 (10 mg/kg; Cayman Chemical), respectively. Tissue samples from colon, spleen, and mesenteric lymph nodes (MLN) were collected for protein, RNA, histology and *C. jejuni* culture assays as described previously (13). Histological images were acquired using a DP71 camera and DP Controller 3.1.1.276 (Olympus), and intestinal inflammation was scored on a scale of 0–4 as described before (12, 13). Neutrophils in colonic tissues were identified based on morphological features using H&E stained sections and counted in 5 fields of view/mouse using a microscope. Data were expressed as average counts/mouse.

### Neutrophil depletion and IL-10 receptor blockade

*II10*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice were infected with *C. jejuni* and injected with anti-Gr1 antibody (i.p. 0.5 mg/mouse, at D0 and D3; clone: RB6-8C5; BioXcell) for 6 days to deplete neutrophil as described in a previous reports (23). We selected a 6 day experimental time instead of the typical 12 days because neutrophil depletion is less effective after 6 days (Sun and Jobin, personal observation). To block IL-10 signaling, antibiotic treated and *C. jejuni* infected *Wt* and *Pi3k $\gamma$* <sup>-/-</sup> mice were injected with anti-IL-10R antibody (i.p. 0.5 mg/mouse, every 3 days; Clone: 1B1.3A; BioXcell) for 14 days as described (24). At the end of the experiment, mice were euthanized using CO<sub>2</sub> intoxication and death was ensured by performing cervical dislocation. Colons were resected and processed for H&E staining and colitis evaluation.

### Western blotting

A segment of the distal colon was lysed in 300  $\mu$ l Laemmli buffer, homogenized and heated at 95 °C for 5 min. 20  $\mu$ g of total protein were separated by SDS-PAGE and transferred to nitrocellulose membranes. Targeted protein was detected using enhanced chemiluminescence reaction (ECL) as described previously (25). Primary antibodies used were phosphor-AKT (S473), phosphor-p70S6K (T389), total AKT (all from Cell Signaling) and EGFP (Sigma). The density of Western blot bands was quantified using ImageJ and data were normalized to total AKT control.

### Neutrophil isolation and migration assay

Neutrophils from the peripheral blood were isolated as described (26). Briefly, blood (~1 ml/mouse, 8 mice/group) from *Wt* and *Pi3k*<sup>-/-</sup> mice was collected in 5mM EDTA by cardiac puncture. The blood was diluted with 0.15M NaCl, loaded on a single layer of 69.2% Percoll and centrifuged at 1500 $\times$  g for 20 min at room temperature. Neutrophils were recovered at

the bottom layer of the gradients, and contaminating erythrocytes were lysed by hypotonic shock. Neutrophil purity was assessed using Wright-Giemsa staining and was found to be > 98 %. Cell migration assay was performed immediately after purification. A total of  $5 \times 10^5$  neutrophils were added in the top chamber of a Transwells (12 wells with 3  $\mu\text{m}$  pore; Corning Inc., Corning, NY) and CXCL-2 (250 ng/mL; R&D Systems) was added to the bottom wells. RPMI 1640 medium without CXCL-2 was used as a negative control. Transwells were then incubated for 2 h in humidified air and 5%  $\text{CO}_2$ . Neutrophils migrated into the bottom wells were imaged using a DP71 camera and DP Controller 3.1.1.276 (Olympus) and enumerated using a hemocytometer (Sigma-Aldrich). Cell viability was more than 95% as judged by trypan blue exclusion.

### Enhanced GFP (EGFP) macro-imaging

Following infection and various treatment, *Il10*<sup>-/-</sup>; NF- $\kappa\text{B}^{\text{EGFP}}$  mice were sacrificed, and the colon and cecum were removed and immediately imaged using a charge-coupled device camera in a light-tight imaging box with a dual-filtered light source and emission filters specific for EGFP (LT-99D2 Illumatools; Lighttools Research).

### Fluorescence in situ hybridization (FISH)

Cy3-tagged 5' AGCTAACACACCTTATACCG3' was used to probe the presence of *C. jejuni* in the intestinal tissue sections as previously described (13). Briefly, tissues were deparaffinized, hybridized with the probe, washed, mounted in DAPI medium and imaged using a Zeiss LSM710 Spectral Confocal Laser Scanning Microscope system with ZEN 2008 software. Acquired images were analyzed using BioimageXD (27).

### Immunohistochemistry (IHC)

Neutrophils in intestinal tissue were detected using anti-myeloperoxidase (MPO) IHC as described previously (13). Briefly, intestinal tissue sections were deparaffinized, blocked and incubated with an anti-MPO antibody (1:400; Thermo Scientific) overnight. After incubation with anti-rabbit biotinylated antibody, ABC (Vectastain ABC Elite Kit, Vector Laboratories), DAB (Dako) and hematoxylin (Fisher Scientific), the sections were imaged on an Olympus microscope using DP 71 camera and DP Controller 3.1.1.276 (Olympus).

### C. jejuni quantification in tissues

MLN and spleen were aseptically resected. Colon tissue was opened, resected and washed three times in sterile PBS. The tissues were weighed, homogenized in PBS, serially diluted and plated on *Campylobacter* selective blood plates (Remel) for 48 h at 37 °C using the GasPak system (BD). *C. jejuni* colonies were counted and data presented as colony forming unit (cfu)/g tissue.

### Real time RT-PCR

Total RNA from intestinal tissues was extracted using TRIzol (Invitrogen) following the manufacture's guide. cDNA was reverse-transcribed using M-MLV (Invitrogen). Proinflammatory *Il1 $\beta$* , *Cxcl2*, *Il17a* and *Tnfa* mRNA expression levels were measured using SYBR Green PCR Master mix (Applied Biosystems) on an ABI 7900HT Fast Real-Time PCR System and normalized to *Gapdh*. The PCR primers used were reported previously. (13) The PCR reactions were performed for 40 cycles according to the manufacturer's recommendation, and RNA fold changes were calculated using the  $\Delta\Delta\text{Ct}$  method.

### Primary splenocyte isolation and *C. jejuni* infection

Splenocytes were isolated as described previously.<sup>13</sup> Briefly, *Wt* and *Pi3k $\gamma$* <sup>-/-</sup> mice (8–12 wk-old) were sacrificed, spleens were resected and homogenized in RPMI 1640 medium

supplemented with 2% fetal bovine serum (FBS), 2mM L-glutamine and 50 $\mu$ M 2-mercaptoethanol. Red blood cells were lysed, and cells were filtered through a 70  $\mu$ m strainer, centrifuged, resuspended in the 2% FBS RPMI 1640 medium and plated at  $1 \times 10^6$  cells/well in 6-well plates. Cells were infected with *C. jejuni* (MOI 50) for 4h in triplicates. Cells were then collected by centrifugation and lysed in TRIzol (Invitrogen) for RNA extraction.

### C. jejuni epithelial cell translocation assay

Murine rectal carcinoma epithelial CMT-93 cells ( $1 \times 10^6$ ) were plated onto 12-well Transwells (Corning Inc., Corning, NY) in DMEM media containing 10% FBS and 2mM L-glutamine. Upon reached confluency (monolayer), the medium was changed to 1% FBS medium and  $10^8$  *C. jejuni* was added to the upper inserts in presence or absence of 10  $\mu$ M AS252424. Aliquot of medium from bottom wells was collected every hr for 5 hrs, serially diluted and cultured on Remel plates as described before (13). Translocated *C. jejuni* was reported as CFU/ml at each time point.

### Statistical analysis

Values are shown as mean  $\pm$  SEM as indicated. Differences between groups were analyzed using the nonparametric Mann-Whitney U test. Experiments were considered statistically significant if *P* values  $< 0.05$ . All calculations were performed using Prism 5.0 software.

## RESULTS

### Innate immune cells mediate *C. jejuni*-induced colitis

We have previously demonstrated using antibody depletion approach that *C. jejuni*-induced colitis in *Il10*<sup>-/-</sup> mice is CD4 independent (13). To further establish the role of innate and adaptive immunity in campylobacteriosis, we utilized germ-free *Il10*<sup>-/-</sup>; *Rag2*<sup>-/-</sup> mice. Germ-free *Il10*<sup>-/-</sup> and *Il10*<sup>-/-</sup>; *Rag2*<sup>-/-</sup> mice were transferred to specific pathogen free (SPF) housing and immediately gavaged with a single dose of *C. jejuni* ( $10^9$  CFU/mouse). After 12 days, as previously reported, *C. jejuni* induced severe intestinal inflammation in *Il10*<sup>-/-</sup> mice as showed by extensive immune cell infiltration, epithelial damage, goblet cell depletion and crypt hyperplasia and abscesses compared to uninfected mice (Figures 1A-B). Interestingly, the absence of T and B cells did not impact the severity of colitis, as *C. jejuni*-infected *Il10*<sup>-/-</sup>; *Rag2*<sup>-/-</sup> and *Il10*<sup>-/-</sup> mice developed comparable levels of intestinal inflammation. Similarly, *C. jejuni*-induced *Il1 $\beta$* , *Cxcl2* and *Il17a* mRNA accumulation was not significantly different between *Il10*<sup>-/-</sup>; *Rag2*<sup>-/-</sup> and *Il10*<sup>-/-</sup> mice (Figure 1C). Altogether, these observations indicate that *C. jejuni*-induced intestinal inflammation is predominantly mediated by innate immune cells during the early onset of campylobacteriosis (12 days).

### PI3K signaling mediates *C. jejuni*-induced colitis

We previously showed that mTOR mediates *C. jejuni*-induced colitis (13) and since PI3K signaling is a potential upstream regulators of mTOR, we hypothesized that this pathway plays an important role in campylobacteriosis. To test this hypothesis, *C. jejuni*-infected germ-free *Il10*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice were i.p. injected daily with either vehicle (5% DMSO PBS) or with the pharmacological PI3K pan-inhibitor wortmannin (1.4 mg/kg body weight) for 12 days. As seen in Figures 2A–B, *C. jejuni*-induced colitis and crypt abscesses were reduced in wortmannin-treated mice compared to vehicle-treated mice. Western blot analysis demonstrated reduction of *C. jejuni*-induced Akt phosphorylation (S473) in colonic lysates from wortmannin-treated, *C. jejuni*-infected mice (Figure 2C). Moreover, *C. jejuni*-induced AKT phosphorylation (S473) in colonic lysates was not impaired in *Il10*<sup>-/-</sup>;



*Rag2*<sup>-/-</sup> mice, suggesting that lymphocytes are not the main contributor of Akt phosphorylation (Supplemental Figure 1).

To evaluate whole body transcriptional response, we infected *I110*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice with *C. jejuni* and determined the level of NF- $\kappa$ B-driven EGFP expression. *C. jejuni*-induced colonic EGFP expression in *I110*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice was attenuated in wortmannin-treated mice compared to vehicle-treated mice (Figures 2C–D). In addition, wortmannin blocked *C. jejuni*-induced NF- $\kappa$ B dependent *I11 $\beta$* , *Cxcl2* and *I117a* mRNA accumulation by 50%, 77% and 78% respectively in *I110*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice compared to vehicle-treated, infected mice (Figure 2E). These findings indicate that PI3K signaling is involved in *C. jejuni*-mediated intestinal inflammation.

### PI3K $\gamma$ mediates *C. jejuni*-induced colitis

Since neutrophil infiltration and crypt abscesses are hallmarks of campylobacteriosis in both human and in the *I110*<sup>-/-</sup> murine model (13, 15), we speculated that signal-induced neutrophil recruitment/activation would be important in host pathogenesis. Among PI3K family members, the class I B PI3K $\gamma$  has been implicated in leukocyte migration and activation. To establish the role of PI3K $\gamma$  in campylobacteriosis, germ-free *I110*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice were gavaged with a single dose of *C. jejuni* (10<sup>9</sup> CFU/mouse) and i.p. injected daily with PI3K $\gamma$  specific inhibitor AS252424 (10 mg/kg body weight) or vehicle control (5% DMSO PBS) for 6 days. Interestingly, *C. jejuni*-induced colitis was reduced in AS252424-treated *I110*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice compared to vehicle-treated mice (Figure 3A–B). Western blot analysis (Figure 3C) demonstrated a modest reduction (Figure 3D) of AKT phosphorylation (S473) but an evident attenuation (34%) of p70S6K phosphorylation (T389) in colonic extracts from AS252424-treated, *C. jejuni*-infected *I110*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice. In addition, induction of EGFP expression (NF- $\kappa$ B activity) in the colon of *C. jejuni* infected *I110*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice was reduced in AS252424-treated mice compared to control vehicle-treated mice (Figures 3C–D). We next examined the impact of PI3K $\gamma$  on expression of NF- $\kappa$ B-dependent proinflammatory mediators involved in bacterial host responses. AS252424 treatment blocked *C. jejuni*-induced *I11 $\beta$* , *Cxcl2* and *I117a* mRNA accumulation by 77%, 73% and 72% respectively compared to vehicle-treated, infected *I110*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice (Figure 3E).

To gain specificity over the pharmacological targeting approach, we next utilized *Pi3k $\gamma$* <sup>-/-</sup> mice. Antibiotic treatment has been shown to enhance *C. jejuni* colonization in *Wt* mice (13). Interestingly, antibiotic-treated *I110*<sup>-/-</sup> mice displayed severe colitis at 2 weeks, but antibiotic-treated SPF *Wt* and *Pi3k $\gamma$* <sup>-/-</sup> mice were resistant to *C. jejuni* induced colitis (Figures 4A and C). To enhance susceptibility of *Wt* and *Pi3k $\gamma$* <sup>-/-</sup> mice to *C. jejuni*-induced colitis, we emulated the *I110* knockout phenotype by using an antibody blocking the IL-10 receptor (IL-10R). Antibiotic-treated *Wt* and *Pi3k $\gamma$* <sup>-/-</sup> mice were gavaged with *C. jejuni* and then i.p. injected with anti-IL-10R antibody (500 $\mu$ g/mouse) every 3 days for 2 weeks. As predicted, anti-IL-10R-treated *Wt* mice developed colitis following *C. jejuni* infection, albeit to a slightly lower extent than *I110*<sup>-/-</sup> mice (Figures 4B–C). In agreement with our pharmacologic studies, *C. jejuni*-induced intestinal inflammation was strongly attenuated in anti-IL-10R-treated *Pi3k $\gamma$* <sup>-/-</sup> mice compared to anti-IL-10R-treated *Wt* mice. No evidence of intestinal inflammation was observed in uninfected *Wt* mice treated with anti-IL-10R antibody alone. Western blot analysis demonstrated a slight reduction of AKT phosphorylation (S473) but a strong blockade (68%) of p70S6K phosphorylation (T389) in intestinal lysates from IL-10R-blocked, *C. jejuni*-infected *Pi3k $\gamma$* <sup>-/-</sup> mice compared to *Wt* mice (Figure 4D). In accordance with the histological score, the absence of PI3K $\gamma$  strongly reduced *C. jejuni*-induced *I11 $\beta$* , *Cxcl2* and *I117a* mRNA accumulation (98.3%, 98.2% and 98.4% respectively) in IL-10R-blocked *Pi3k $\gamma$* <sup>-/-</sup> mice, compared to treated *Wt* mice (Figure 4E). To determine whether absence of PI3K $\gamma$  signaling is directly responsible for decreased

*C. jejuni*-induced inflammatory gene expression, we isolated splenocytes from *Wt* and *Pi3k $\gamma$ <sup>-/-</sup>* mice. Interestingly, *C. jejuni*-induced *I11 $\beta$* , *Cxcl2*, *I117a* and *Tnfa* mRNA expression was comparable between splenocytes obtained from *Pi3k $\gamma$ <sup>-/-</sup>* and *Wt* mice (Supplemental Figure 2). These results suggest that PI3K $\gamma$  signaling does not directly regulate *C. jejuni* induced proinflammatory gene expression.

### PI3K $\gamma$ mediates *C. jejuni* invasion

Since *C. jejuni* is an invasive intestinal pathogenic bacterium, we next investigated the impact of PI3K $\gamma$  signaling on *C. jejuni* invasion into intra- and extra-intestinal tissues. Following infection and treatment with the PI3K $\gamma$  inhibitor AS252424, *C. jejuni* DNA was visualized in the colon of *I110<sup>-/-</sup>*; NF- $\kappa$ B<sup>EGFP</sup> mice using fluorescence in situ hybridization (FISH) and confocal microscopy imaging. Remarkably, while *C. jejuni* was abundant in inflamed crypts and lamina propria of vehicle-treated mice, the bacterium was barely detectable in AS252424-treated mice (Figure 5A). To assess the amount of viable *C. jejuni* in intestinal and extra-intestinal tissues, we aseptically collected samples from the colon, spleen and MLN and enumerated *C. jejuni* on Remel *Campylobacter* selective plates. Consistent with FISH results, AS252424 treatment decreased the amount of viable *C. jejuni* in colon and MLN by 97% and 90% compared to *C. jejuni*-infected, vehicle-treated mice (Figure 5B). Moreover, AS252424 treatment strongly reduced the levels of viable *C. jejuni* in the spleen, compared to vehicle-treated, infected mice. Again, to confirm our findings from pharmacologic studies, we infected *Pi3k $\gamma$ <sup>-/-</sup>* mice treated with IL-10R blocking antibody and assessed *C. jejuni* invasion using FISH. *C. jejuni* was detected deeply inside the intestinal section of anti-IL-10R-treated *Wt* mice, whereas anti-IL-10R-treated *Pi3k $\gamma$ <sup>-/-</sup>* mice exhibited a strong reduction in bacterial invasion into colonic tissues (Figure 5C). To determine whether PI3K $\gamma$  signaling derived from epithelial cells directly affects *C. jejuni* invasion, we infected a monolayer of murine colonic CMT-93 cells with *C. jejuni* in the presence or absence of AS252424 and measured bacterial translocation using a transwell culture system. As shown in supplemental Figure 3, PI3K $\gamma$  inhibition did not prevent *C. jejuni* translocation. Taken together, these results demonstrate that *C. jejuni* invasion into intestinal and extra-intestinal tissue is dependent upon functional PI3K $\gamma$  signaling, likely originating from immune cells.

### Neutrophil infiltration promotes *C. jejuni*-induced colitis

As previously reported, crypt abscesses and neutrophil infiltration is predominant in *C. jejuni*-infected *I110<sup>-/-</sup>* mice (13). As seen in Figure 6A, *C. jejuni* infection of *I110<sup>-/-</sup>* mice induced an average of greater than 71 colonic crypt abscesses per 100 crypts. Remarkably, *C. jejuni*-induced crypt abscesses were reduced by 95% in AS252424-treated *I110<sup>-/-</sup>* mice compared to vehicle-treated mice. In accordance with this finding, MPO staining revealed that *C. jejuni*-induced neutrophil infiltration into colonic tissues was strongly reduced in the presence of AS252424 (Figure 6B). Since PI3K $\gamma$  is implicated in neutrophil migration (20), we next evaluated peripheral blood neutrophil motility in response to the chemokine CXCL-2 using a transwell migration assay. Migration was reduced by 64% in neutrophils isolated from *Pi3k $\gamma$ <sup>-/-</sup>* mice compared to *Wt* cells (Figures 6C and D). Together our observations demonstrate that suppression of *C. jejuni*-induced colitis by pharmacologic inhibition of PI3K $\gamma$  is associated with an impaired neutrophil migration/infiltration and subsequent crypt abscess formation. To directly assess the role of neutrophils in *C. jejuni*-induced colitis, we depleted these cells using an anti-Gr-1 antibody (i.p. every 3 days for 6 days). Depletion of neutrophils attenuated *C. jejuni*-induced colitis in *I110<sup>-/-</sup>* mice, as demonstrated by the significant reduction of histological scores (Figures 7A–B), which was correlated with reduced MPO staining (Figure 7C). Numbers of colonic neutrophils were reduced by more than 92% in anti-Gr-1 antibody-treated, *C. jejuni* infected mice compared to untreated mice (Figure 7D). To determine the effect of neutrophil depletion on *C. jejuni*

invasion, we visualized *C. jejuni* presence in colon tissues using FISH assay. Interestingly, although neutrophils were depleted, *C. jejuni* invasion into the colon was strongly attenuated (Figure 7E), suggesting that other immune cells such as macrophages and dendritic cells are important in eliminating invading *C. jejuni*. Collectively, these results demonstrate that PI3K $\gamma$  signaling is essential for *C. jejuni* induced intestinal inflammation, likely by modulating neutrophil infiltration and migration into the intestinal tissues.

## DISCUSSION

The molecular and cellular events leading to campylobacteriosis and its associated pathological features remain poorly understood. We previously reported that *C. jejuni* induced intestinal inflammation through mTOR signaling, a downstream target of the PI3K pathway, which was associated with neutrophil infiltration and tissue damage (13). However, the molecular events leading to *C. jejuni* induced neutrophil migration and their functional consequence on intestinal inflammation has not been addressed. In addition, because PI3Ks form a large family of kinases, the subunit responsible for neutrophil activation and migration following *C. jejuni* infection is unclear. In this study, we uncover the key role of innate immune cells, especially neutrophils in *C. jejuni*-induced intestinal inflammation. In addition, we identified PI3K $\gamma$  signaling as key event leading to campylobacteriosis.

Among the large family of PI3Ks, PI3K $\gamma$  is predominantly expressed in immune cells (19, 20). Disruption of PI3K $\gamma$  attenuates *E. coli*-induced lung injury resulting from neutrophil infiltration (28). Similarly, a reduction of neutrophil-mediated rheumatoid arthritis is observed in *Pi3k $\gamma$ <sup>-/-</sup>* mice (29). Our study demonstrates that *C. jejuni*-induced colitis can be alleviated by inactivation of PI3K $\gamma$  signaling using either pharmacological or genetic manipulation.

Using FISH and culture assays, we observed that PI3K $\gamma$  signaling promotes *C. jejuni* invasion into colon, MLN and spleen of *Il10<sup>-/-</sup>* mice. Immunohistochemistry assays revealed massive infiltration of neutrophils into the colon following *C. jejuni* infection, an effect attenuated by inactivation of PI3K $\gamma$ . Moreover, depletion of neutrophils using anti-Gr1 antibody reduced *C. jejuni* induced intestinal inflammation by ~40%, an effect comparable to inactivation of PI3K $\gamma$ . Taken together, our findings highlight the essential role of PI3K $\gamma$  signaling and neutrophils in *C. jejuni* pathogenesis.

The contribution of innate and adaptive immune cells in host response to *C. jejuni* infection is not well understood. Adaptive immunity has been documented to protect the host against *C. jejuni*-induced diarrhea and intestinal inflammation in CD4 deficient HIV patients (30). On the other hand, the plasma of *C. jejuni* infected patients have been shown to contain anti-ganglioside 1 IgG (31) mimicry between the core lipooligosaccharides of *C. jejuni* and human gangliosides which may be associated with the development of Guillain-Barre Syndrome (3). Interestingly, adaptive immunity may not be essential for early intestinal inflammation as *C. jejuni* induced colitis is similar between *Il10<sup>-/-</sup>*; *Rag2<sup>-/-</sup>* mice and *Il10<sup>-/-</sup>* mice. This finding strongly suggests that innate immune cells are key cellular components responsible for the acute state (~12 days) of campylobacteriosis in our model. In addition, IHC analysis in conjunction with cell migration and depletion studies strongly point to the key role of neutrophils in campylobacteriosis. Therefore, although persistent *C. jejuni* infection triggers an adaptive immune response, the initial responses and associated tissue damage is mediated by neutrophils.

Following enteric bacterial infection, neutrophils are rapidly recruited into intestinal tissues where they eliminate microorganisms through phagocytosis and degranulation-mediated



bacterial killing (32). However, overzealous neutrophil recruitment into a defined location like intestinal crypts often leads to significant host tissue damage. Neutrophil-induced tissue damage has been reported in non-infectious diseases such as IBD (33), lung injury (28) and arthritis (29). In *C. jejuni*-infected patients, histological assessment of intestinal tissues has revealed neutrophil infiltration and crypt abscesses (34). Using transmission electron microscopy analysis, we previously showed that crypt microvilli are virtually destroyed by accumulated neutrophils (13). Our current studies demonstrated that antibody-mediated depletion of neutrophils diminished intestinal inflammation and strongly decreased crypt abscess formation.

Although our data have identified neutrophils as key innate cells in *C. jejuni* mediated pathogenesis, the molecular events leading to their recruitment into intestinal crypts is less clear. We have shown a strong induction of the chemokine *Cxcl2* in colonic lysates of *C. jejuni* infected *Il10*<sup>-/-</sup> mice. *In vitro* experiments indicate that intestinal epithelial cells (12) and splenocytes up-regulate *Cxcl2* gene expression following *C. jejuni* infection. From these data, one could speculate that *C. jejuni* invasion leads to the secretion of various chemo-attractants including CXCL-2, from immune and non-immune cells, which then promote recruitment of neutrophils. Interestingly, *C. jejuni*-induced proinflammatory gene expression including *Cxcl2* is comparable in splenocytes isolated from *Pi3kγ*<sup>-/-</sup> and *Wt* mice and blocking PI3Kγ doesn't attenuate *C. jejuni* invasion through CMT-93 epithelial monolayer. We conclude that PI3Kγ signaling predominantly mediates its inhibitory effect through regulation of neutrophil migration. Interestingly, although neutrophils most likely participate in the removal of invading *C. jejuni*, FISH assay showed a strong decrease of the bacterium in colonic tissues of GR-1-treated mice. This finding suggests that other innate cells such as macrophages and dendritic cells are important for *C. jejuni* eradication in the colon. In this scenario, the beneficial impact of neutrophils in *C. jejuni* elimination is outweighed by the tissue destructive capacity of these innate cells and associated damage to the epithelial barrier. It is likely that *C. jejuni* located in the luminal compartment profits from this impaired barrier function to further invade the colonic tissues.

Presently, the primary treatment for campylobacteriosis resorts to antibiotics. However, antibiotic treatment is constrained by multiple factors, including minimal effectiveness in the late course of disease, a negligible reduction in disease duration (1.5 days), increased antibiotic resistance, and the risk of harmful eradication of normal flora (35). Thus alternatives to antibiotics are imperative for treating infectious enteric pathogens, and immunotherapy targeting specific signaling pathways such as PI3Kγ may provide such an alternative.

In summary, this report defines the critical role of PI3Kγ in mediating the pro-inflammatory effects of *C. jejuni* infection. We report that PI3Kγ mediated neutrophil infiltration plays an active role in the pathogenesis of *C. jejuni* infection. Accordingly, modulation of the cellular/molecular events leading to this process could represent a new therapeutic approach to control campylobacteriosis.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

**Funding:** This research was supported by National Institutes of Health grants DK047700, DK073338, AI082319 to C. Jobin and by P30 DK34987 for the CGIBD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The authors would like to thank Mrs. Brigitte Allard for technical assistance throughout this project. We would like to thank Dr. Janelle Arthur for editorial assistance. We would also like to thank Dr. Robert Bagnell, Mr. Steven Ray and Mrs. Victoria Madden (Microscopy Services Laboratory) and Mr. Robert Currin (Manager, Cell & Molecular Imaging Facility and UNC-Olympus Center), all of UNC-CH, for their assistance with the confocal fluorescent microscopy.

## Abbreviations


<b>MLN</b>	mesenteric lymph nodes
<b>IHC</b>	immunohistochemistry
<b>FISH</b>	fluorescence in situ hybridization

## References

1. CDC. Incidence of laboratory-confirmed bacterial and parasitic infections, and postdiarrheal hemolytic uremic syndrome (HUS), by year and pathogen, Foodborne Diseases Active Surveillance Network (FoodNet), United States, 1996 – 2011. Centers for Disease Control and Prevention; 2012. <http://www.cdc.gov/foodnet/data/trends/tables/table2a-b.html#table-2b>
2. Blaser MJ. Epidemiologic and clinical features of *Campylobacter jejuni* infections. *J Infect Dis.* 1997; 176(Suppl 2):S103–105. [PubMed: 9396691]
3. Nachamkin I. Chronic effects of *Campylobacter* infection. *Microbes Infect.* 2002; 4:399–403. [PubMed: 11932190]
4. Mortensen NP, Kuijf ML, Ang CW, Schiellerup P, Krogfelt KA, Jacobs BC, van Belkum A, Endtz HP, Bergman MP. Sialylation of *Campylobacter jejuni* lipo-oligosaccharides is associated with severe gastro-enteritis and reactive arthritis. *Microbes Infect.* 2009; 11:988–994. [PubMed: 19631279]
5. Gradel KO, Nielsen HL, Schønheyder HC, Ejlersen T, Kristensen B, Nielsen H. Increased Short- and Long-Term Risk of Inflammatory Bowel Disease After Salmonella or *Campylobacter* Gastroenteritis. *Gastroenterology.* 2009; 137:495–501. [PubMed: 19361507]
6. Qin HY, Wu JC, Tong XD, Sung JJ, Xu HX, Bian ZX. Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. *J Gastroenterol (2010/09/18).* 201010.1007/s00535-00010-00321-00536
7. van den Bruele T, Mourad-Baars PE, Claas EC, van der Plas RN, Kuijper EJ, Bredius RG. *Campylobacter jejuni* bacteremia and *Helicobacter pylori* in a patient with X-linked agammaglobulinemia. *Eur J Clin Microbiol Infect Dis.* 2010; 29:1315–1319. [PubMed: 20556465]
8. Valenza G, Frosch M, Abele-Horn M. Antimicrobial susceptibility of clinical *Campylobacter* isolates collected at a German university hospital during the period 2006–2008. *Scand J Infect Dis.* 2010; 42:57–60. [PubMed: 20055727]
9. Young KT, Davis LM, Dirit VJ. *Campylobacter jejuni*: molecular biology and pathogenesis. *Nat Rev Microbiol.* 2007; 5:665–679. [PubMed: 17703225]
10. Fouts DE, Mongodin EF, Mandrell RE, Miller WG, Rasko DA, Ravel J, Brinkac LM, DeBoy RT, Parker CT, Daugherty SC, Dodson RJ, Durkin AS, Madupu R, Sullivan SA, Shetty JU, Ayodeji MA, Shvartsbeyn A, Schatz MC, Badger JH, Fraser CM, Nelson KE. Major structural differences and novel potential virulence mechanisms from the genomes of multiple *campylobacter* species. *PLoS Biol.* 2005; 3:e15. [PubMed: 15660156]
11. Hofreuter D, Tsai J, Watson RO, Novik V, Altman B, Benitez M, Clark C, Perbost C, Jarvie T, Du L, Galan JE. Unique features of a highly pathogenic *Campylobacter jejuni* strain. *Infect Immun.* 2006; 74:4694–4707. [PubMed: 16861657]
12. Lippert E, Karrasch T, Sun X, Allard B, Herfarth HH, Threadgill D, Jobin C. Gnotobiotic IL-10; NF-kappaB mice develop rapid and severe colitis following *Campylobacter jejuni* infection. *PLoS One.* 2009; 4:e7413. [PubMed: 19841748]
13. Sun X, Threadgill D, Jobin C. *Campylobacter jejuni* Induces Colitis Through Activation of Mammalian Target of Rapamycin Signaling. *Gastroenterology.* 2012; 142:86–95. e85. [PubMed: 21963787]

14. Mansfield L, Patterson J, Fierro B, Murphy A, Rathinam V, Kopper J, Barbu N, Onifade T, Bell J. Genetic background of IL-10<sup>-/-</sup> mice alters host-pathogen interactions with *Campylobacter jejuni* and influences disease phenotype. *Microbial Pathogenesis*. 2008; 45:241–257. [PubMed: 18586081]
15. Blaser MJ, Parsons RB, Wang WL. Acute colitis caused by *Campylobacter fetus* ss. *jejuni*. *Gastroenterology*. 1980; 78:448–453. [PubMed: 7351284]
16. Rydstrom A, Wick MJ. Monocyte and neutrophil recruitment during oral *Salmonella* infection is driven by MyD88-derived chemokines. *Eur J Immunol*. 2009; 39:3019–3030. [PubMed: 19839009]
17. Koyasu S. The role of PI3K in immune cells. *Nat Immunol*. 2003; 4:313–319. [PubMed: 12660731]
18. Gunzl P, Schabbauer G. Recent advances in the genetic analysis of PTEN and PI3K innate immune properties. *Immunobiology*. 2008; 213:759–765. [PubMed: 18926291]
19. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. *Science*. 2000; 287:1046–1049. [PubMed: 10669417]
20. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Itie A, Bouchard D, Kozieradzki I, Joza N, Mak TW, Ohashi PS, Suzuki A, Penninger JM. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. *Science*. 2000; 287:1040–1046. [PubMed: 10669416]
21. Ferguson GJ, Milne L, Kulkarni S, Sasaki T, Walker S, Andrews S, Crabbe T, Finan P, Jones G, Jackson S, Camps M, Rommel C, Wymann M, Hirsch E, Hawkins P, Stephens L. PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. *Nat Cell Biol*. 2007; 9:86–91. [PubMed: 17173040]
22. Korlath JA, Osterholm MT, Judy LA, Forfang JC, Robinson RA. A point-source outbreak of campylobacteriosis associated with consumption of raw milk. *J Infect Dis*. 1985; 152:592–596. [PubMed: 4031557]
23. Ribechini E, Leenen PJM, Lutz MB. Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. *European Journal of Immunology*. 2009; 39:3538–3551. [PubMed: 19830733]
24. Bai F, Town T, Qian F, Wang P, Kamanaka M, Connolly TM, Gate D, Montgomery RR, Flavell RA, Fikrig E. IL-10 signaling blockade controls murine West Nile virus infection. *PLoS Pathog*. 2009; 5:e1000610. [PubMed: 19816558]
25. Muhlbauer M, Chilton PM, Mitchell TC, Jobin C. Impaired Bcl3 Up-regulation Leads to Enhanced Lipopolysaccharide-induced Interleukin (IL)-23P19 Gene Expression in IL-10<sup>-/-</sup> Mice. *Journal of Biological Chemistry*. 2008; 283:14182–14189. [PubMed: 18375954]
26. Boxio R, Bossenmeyer-Pourie C, Steinckwich N, Dournon C, Nusse O. Mouse bone marrow contains large numbers of functionally competent neutrophils. *J Leukoc Biol*. 2004; 75:604–611. [PubMed: 14694182]
27. Kankaanpää P, Pahajoki K, Marjomäki V, Heino J, White D. BioImageXD-New Open Source Free Software for the Processing, Analysis and Visualization of Multidimensional Microscopic Images. *Microscopy Today*. 2006; 14:12–16.
28. Ong E, Gao XP, Predescu D, Broman M, Malik AB. Role of phosphatidylinositol 3-kinase-gamma in mediating lung neutrophil sequestration and vascular injury induced by *E. coli* sepsis. *Am J Physiol Lung Cell Mol Physiol*. 2005; 289:L1094–1103. [PubMed: 16183669]
29. Camps M, Ruckle T, Ji H, Ardisson V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. *Nat Med*. 2005; 11:936–943. [PubMed: 16127437]
30. Snijders F, Kuijper EJ, de Wever B, van der Hoek L, Danner SA, Dankert J. Prevalence of *Campylobacter*-associated diarrhea among patients infected with human immunodeficiency virus. *Clin Infect Dis*. 1997; 24:1107–1113. [PubMed: 9195065]


31. Oomes PG, Jacobs BC, Hazenberg MP, Banffer JR, van der Meche FG. Anti-GM1 IgG antibodies and *Campylobacter* bacteria in Guillain-Barre syndrome: evidence of molecular mimicry. *Ann Neurol.* 1995; 38:170–175. [PubMed: 7654064]
32. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. *Science.* 2004; 303:1532–1535. [PubMed: 15001782]
33. Chin AC, Parkos CA. Neutrophil transepithelial migration and epithelial barrier function in IBD: potential targets for inhibiting neutrophil trafficking. *Ann N Y Acad Sci.* 2006; 1072:276–287. [PubMed: 17057207]
34. van Spreuwel JP, Duursma GC, Meijer CJ, Bax R, Rosekrans PC, Lindeman J. *Campylobacter* colitis: histological immunohistochemical and ultrastructural findings. *Gut.* 1985; 26:945–951. [PubMed: 4029720]
35. Ternhag A, Asikainen T, Giesecke J, Ekdahl K. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with *Campylobacter* species. *Clin Infect Dis.* 2007; 44:696–700. [PubMed: 17278062]



**Figure 1. Innate immune cells mediate *C. jejuni* induced colitis in  $II10^{-/-}$  mice**


Cohorts of 4–7 germ-free  $II10^{-/-}$  and  $II10^{-/-}; Rag2^{-/-}$  mice were transferred to SPF conditions and immediately gavaged with a single dose of  $10^9$  *C. jejuni*/mouse. After 12 days, colons were resected for formalin-fixation, sectioning and H&E staining, or RNA extraction for gene expression analysis. (A) Histological intestinal damage scores of *C. jejuni*-induced inflammation in  $II10^{-/-}$  and  $II10^{-/-}; Rag2^{-/-}$  mice. (B) Quantification of histological intestinal damage score mediated by *C. jejuni* infection. (C) *II1β*, *Cxcl2* and *II17a* mRNA accumulation was quantified using an ABI 7900HT Fast Real-Time PCR System and specific primers and data were normalized to *Gapdh*. All graphs depict mean  $\pm$  SEM. NS,  $P > 0.05$ . Scale bar is 200  $\mu$ m. Results are representative of 3 independent experiments.






**Figure 2. PI3K signaling pathway mediates *C. jejuni*-induced intestinal inflammation in *Il10*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice**

Four cohorts of 4–8 germ-free *Il10*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice were transferred to SPF conditions and immediately gavaged with a single dose of *C. jejuni* ( $10^9$ /mouse) and then i.p. injected with vehicle control (Ctl, 5% DMSO), wortmannin (wort, 1.4 mg/kg body weight) daily for 12 days. (A) H&E representation of intestinal damage. Arrow heads indicate crypt abscesses. (B) Quantification of intestinal inflammation as histological score. (C) Western blot for total and phosphorylated (S473) AKT and EGFP protein levels in pooled colonic lysates of infected mice. (D) Colonic EGFP expression levels were visualized using a CCD camera macroimaging system. (E) *Il1β*, *Cxcl2* and *Il17a* mRNA accumulation was quantified using real time PCR. All graphs depict mean  $\pm$  SEM. \*,  $P < 0.05$ , \*\*,  $P < 0.01$ , \*\*\*,  $P < 0.001$ . Scale bar is 200  $\mu$ m. Results are representative of 3 independent experiments.




**Figure 3. Pharmacological inhibition of PI3K $\gamma$  blocks *C. jejuni*-induced intestinal inflammation in *Il10*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice**

Four cohorts of 4–6 germ-free *Il10*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice were transferred to SPF conditions and infected with *C. jejuni* as described in Figure 1. Mice were i.p. injected with vehicle (5% DMSO) or pharmacological PI3K $\gamma$  inhibitor AS252424 (10 mg/kg body weight) daily for 6 days. (A) H&E representation of intestinal inflammation. (B) Quantitative histological score of intestinal inflammation. (C) Western blot for total and phosphorylated (S473) AKT, phosphorylated p70S6K (T389) and EGFP protein levels in pooled colonic lysates of infected mice. (D) Density of Western blot bands was quantified using ImageJ and normalized to control. (E) Colonic EGFP expression levels were visualized using a CCD camera macroimaging system. (F) *Il1β*, *Cxcl2* and *Il17a* mRNA accumulation was quantified by real time PCR. All graphs depict mean  $\pm$  SEM. \*,  $P < 0.05$ , \*\*,  $P < 0.01$ , NS, not significant. Scale bar is 200  $\mu$ m. Results are representative of 3 independent experiments.




#### Figure 4. PI3K $\gamma$ deficiency attenuates *C. jejuni*-induced intestinal inflammation

Eight cohorts of 4–6 *Wt*, *Il10<sup>-/-</sup>* and *Pi3ky<sup>-/-</sup>* mice were treated with antibiotic for 7 days and then gavaged with a single dose of *C. jejuni* ( $10^9$ /mouse). *Wt* and *Pi3ky<sup>-/-</sup>* mice were injected anti-IL-10R antibody (i.p. 0.5 mg/mouse/every 3 days) to block IL-10 receptors. Mice were sacrificed after 14 days. (A–B) H&E representation of intestinal inflammation. (C) Quantitative histological score of intestinal inflammation. (D) Western blot for phosphorylated AKT (S473), phosphorylated p70S6K (T389) and total AKT protein levels in pooled colonic lysates of infected mice. (E) *Il1 $\beta$* , *Cxcl2* and *Il17a* mRNA accumulation was quantified using real time PCR. Data represent means  $\pm$  SEM. \*,  $P < 0.05$ . Scale bar is 200  $\mu$ m. Results are representative of 2 independent experiments.




**Figure 5. PI3K $\gamma$  signaling promotes *C. jejuni* invasion into colon, MLN and spleen**  
 Cohorts of 4–6 germ-free *Il10*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice, SPF *Wt* and *Pi3k $\gamma$* <sup>-/-</sup> mice were treated and infected as indicated in Figure 3 and 4. (A) *C. jejuni* (red dots) in colonic sections of infected mice was detected using FISH. Scale bar is 10  $\mu$ m. (B) *C. jejuni* bacterial count in the colon, MLN and spleen of vehicle- or AS252424-treated mice. (C) Presence of *C. jejuni* (red dots) in colonic tissue of *Wt* and *Pi3k $\gamma$* <sup>-/-</sup> mice was determined using FISH. Data represent means  $\pm$  SEM. \*  $P < 0.05$ . Results are representative of 3 independent experiments.





**Figure 6. PI3K $\gamma$  mediates neutrophil accumulation and crypt abscesses in *C. jejuni* infected mice**  
 Cohorts of 4–6 germ-free *Il10*<sup>-/-</sup>; NF- $\kappa$ B<sup>EGFP</sup> mice were transferred to SPF conditions and infected/treated as indicated in Figure 3. (A) Number of crypt abscesses in *C. jejuni* infected mice. (B) IHC representation of MPO positive cells (brown dots) in the colon tissue of *C. jejuni* infected mice. (C) Peripheral blood neutrophils were isolated and plated in a transwell system and cells migration in response to CXCL-2 (250 ng/mL) at the bottom well were enumerated. Representative light images of neutrophils migrated into bottom wells. (D) Quantitative measurements of migrated neutrophils. Lower panels (scale bar 20  $\mu$ m) are magnified images of area shown in the upper panels (scale bar 200  $\mu$ m). Data represent means  $\pm$  SEM. \*\*, P < 0.01. Results are representative of 3 independent experiments.





**Figure 7. Neutrophils enhance *C. jejuni*-induced colitis**

Cohorts of 4–6 germ-free *Il10*<sup>-/-</sup>; NF-κB<sup>EGFP</sup> mice were transferred to SPF conditions and infected as in Figure 3. Neutrophils were depleted using anti-Gr1 antibody. (A) H&E representation of intestinal inflammation. (B) Quantitative histological score of intestinal inflammation. (C) IHC representation of MPO positive cells (brown dots) in the colon tissue of *C. jejuni* infected mice. (D) The colonic H&E stained sections were imaged (5 fields/mouse) and neutrophils were identified based on morphological features. Data are presented as average counts/mouse. (E) Presence of *C. jejuni* (red dots) in colonic tissue was determined using FISH. Lower panels (scale bar 20 μm) are magnified images of area shown in the upper panels (scale bar 200 μm). Data represent means ± SEM. \*, P < 0.05. Results are representative of 3 independent experiments.